Algenscribe Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Early Stage VC
  • (Upcoming)

  • Investors
  • 6

Algenscribe General Information

Description

Developer of a gene editing platform designed to improve human health. The company applies a unique toolbox for precise gene editing for Gene Replacement and Base Editing, enabling users to increase the efficiency of homologous recombination and addressing the issue of mutations (indels) linked to the process of gene editing.

Contact Information

Website
www.algenscribe.fr
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 61 Avenue Simone Veil
  • 06200 Nice
  • France
Primary Industry
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 61 Avenue Simone Veil
  • 06200 Nice
  • France

Algenscribe Timeline

20232024202520262027
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Algenscribe Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Early Stage VC 01-Jan-2027 Upcoming Startup
7. Debt - General 01-Jun-2026 Completed Startup
6. Early Stage VC 25-Nov-2025 Completed Startup
5. Angel (individual) 01-Nov-2025 Completed Startup
4. Seed Round Completed Startup
3. Angel (individual) 16-Jun-2023 Completed Startup
2. Accelerator/Incubator Completed Startup
1. Accelerator/Incubator Completed Startup
To view Algenscribe’s complete valuation and funding history, request access »

Algenscribe Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
To view Algenscribe’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Algenscribe Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a gene editing platform designed to improve human health. The company applies a unique toolbox for precise
Biotechnology
Nice, France
3 As of 2026

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Algenscribe Competitors (1)

One of Algenscribe’s competitors is Prime Medicine, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Prime Medicine Formerly VC-backed Cambridge, MA
You’re viewing 1 of 1 competitors. Get the full list »

Algenscribe Patents

  • 12

    Total Documents Applications and Grants

  • Total Patents Families

  • 6

    Granted

  • 5

    Pending

  • Expiring in next 12 mo

Algenscribe Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2019276360-A1 Gene targeting Active 01-Jun-2018
AU-2019276360-B2 Gene targeting Active 01-Jun-2018
AU-2019276370-A1 Gene targeting Active 01-Jun-2018
AU-2019276370-B2 Gene targeting Active 01-Jun-2018
AU-2025271518-A1 Gene targeting Pending 01-Jun-2018 C12N15/8213
To view Algenscribe’s complete patent history, request access »

Algenscribe Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Algenscribe Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bpifrance Sovereign Wealth Fund Minority
Eurobiomed Accelerator/Incubator Minority
Incubator Provence Côte d'Azur Accelerator/Incubator Minority
L'Agence Nationale de la Recherche Government Minority
Medicen Corporation
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial

Algenscribe FAQs

  • When was Algenscribe founded?

    Algenscribe was founded in 2022.

  • Where is Algenscribe headquartered?

    Algenscribe is headquartered in Nice, France.

  • What is the size of Algenscribe?

    Algenscribe has 3 total employees.

  • What industry is Algenscribe in?

    Algenscribe’s primary industry is Biotechnology.

  • Is Algenscribe a private or public company?

    Algenscribe is a Private company.

  • What is Algenscribe’s current revenue?

    The current revenue for Algenscribe is .

  • How much funding has Algenscribe raised over time?

    Algenscribe has raised $1.58M.

  • Who are Algenscribe’s investors?

    Bpifrance, Eurobiomed, Incubator Provence Côte d'Azur, L'Agence Nationale de la Recherche, and Medicen are 5 of 6 investors who have invested in Algenscribe.

  • Who are Algenscribe’s competitors?

    Prime Medicine is a competitor of Algenscribe.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process